SRPT Latest Press Releases

-- October 14, 2026 --

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting Business Wire 8:30 AM

-- October 5, 2026 --

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT Business Wire 1:26 PM

-- September 30, 2026 --

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:30 PM

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne Business Wire 8:30 AM

-- September 25, 2026 --

Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress Business Wire 8:30 AM

-- September 24, 2026 --

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting Business Wire 8:30 AM

-- September 8, 2026 --

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year Business Wire 9:00 AM

-- September 4, 2026 --

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT PRNewswire 10:01 PM

-- August 31, 2026 --

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference Business Wire 4:30 PM

-- August 24, 2026 --

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT Business Wire 12:02 PM

-- August 5, 2026 --

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments Business Wire 4:05 PM

-- July 29, 2026 --

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:00 PM

-- July 27, 2026 --

Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer Business Wire 8:30 AM

-- July 22, 2026 --

Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results Business Wire 8:30 AM

-- July 13, 2026 --

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT) Globe Newswire 9:46 AM

-- June 30, 2026 --

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:25 PM

Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45 and VYONDYS 53 Business Wire 8:30 AM

-- June 3, 2026 --

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion Globe Newswire 8:30 AM

-- June 1, 2026 --

Sarepta Therapeutics to Participate in Upcoming Investor Conferences Business Wire 4:30 PM

Market Data Delayed 15 Minutes